Science
Mechanism of Action
This advanced ingredient operates through two distinct yet complementary mechanisms. The SH-PENTAPEPTIDE-12 SP component mimics a 'type C botulinum toxin peptide,' working to relax facial muscles by inhibiting neurotransmitter release at the neuromuscular junction. It achieves this by competing for and destabilizing SNARE complexes, thereby reducing acetylcholine release and softening the appearance of wrinkles. Concurrently, the Tranexamoyl moiety targets hyperpigmentation by inhibiting tyrosinase, a key enzyme in melanin synthesis, and reducing the expression of MITF, which regulates melanocyte activity. This combined action leads to diminished melasma, dark spots, and overall skin brightening.
Research
Clinical Evidence
Medium confidenceN/A
Transparency
Dusting Analysis
The Formula
Formulation
Stability
Related Tranexamoyl peptides, such as Tranexamoyl Dipeptide-23, demonstrate enhanced stability and effectiveness in formulations due to the tranexamic acid (TXA) modification.
Safety
Safety Profile
While TRANEXAMOYL SH-PENTAPEPTIDE-12 SP has not been reviewed by CIR, SCCS, or FDA, related Tranexamoyl peptides (e.g., Tranexamoyl Dipeptide-23) have shown safety in cytotoxicity studies. The SH-PENTAPEPTIDE-12 SP component is generally considered to have low safety concerns, with 'No penalty' reported across categories by INCI Beauty.
Your Skin
Skin Compatibility
Our Assessment
Verdict
TRANEXAMOYL SH-PENTAPEPTIDE-12 SP is a valuable multi-functional ingredient, offering targeted action against both dynamic wrinkles and various forms of hyperpigmentation, making it a powerful addition to comprehensive anti-aging and brightening regimens.
Related
Similar Ingredients
Finding similar ingredients…
References
Sources